UroAlert - GU Oncology Weekly

October 09, 2025

Videos

Peer-to-Peer Clinical Conversations

STARBURST-1: A Cohort Study to Develop a Complete Response Signature in Bladder Cancer - Alexandra Masson-Lecomte

Alexandra Masson-Lecomte introduces the STARBURST project, addressing critical questions around defining clinical complete response after neoadjuvant treatment for muscle-invasive bladder cancer.

Diagnostic and Staging Approaches for Localized Neuroendocrine Prostate Cancer - Joshua Lang & Rana McKay

Joshua Lang

Rana McKay and Joshua Lang discuss the management of localized small cell and neuroendocrine prostate cancer.

Beyond the Abstracts

Clinical, Pathologic, and Genetic Correlates of Nuclear Grade in von Hippel-Lindau-associated Renal Cell Carcinoma - Beyond the Abstract

Prognostic Significance of Pathologic Response to Neoadjuvant Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder with Histologic Subtype - Beyond the Abstract

Conference Coverage

SCS AUA 2025: Preliminary Results from LEGEND: A Phase 2 Study of Detalimogene Voraplasmid, a Novel, Investigational, Non-Viral Genetic Medicine for High-Risk NMIBC

SCS AUA 2025: Piloting a Web-Based Urinary Diversion Decision Aid

SCS AUA 2025: TAR-200 Monotherapy in Patients with BCG-Unresponsive High-Risk NMIBC CIS: 1-Year Durability and Patient Reported Outcomes from SunRISe-1

SCS AUA 2025: Patient-Reported Barriers, Social Determinants, and Racial Disparities in RCC: Findings from the United States

SCS AUA 2025: Association Between Prior Pelvic Radiotherapy and Surgical Outcomes of Radical Cystectomy for Bladder Cancer: Analysis of National Surgical Quality Improvement Program Targeted Cystectomy Database

Physician-Scientist Review Articles

Functional Interrogation of the Impact of ERCC2 Mutations in Bladder Cancer on Cisplatin Sensitivity - Expert Commentary

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in Cisplatin-Ineligible Patients with MIBC - Expert Commentary

Treatment of Oligometastatic Bladder Cancer with SBRT - Expert Commentary

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker.

Effect of neoadjuvant chemotherapy on years of life lost in radical cystectomy-treated T2N0M0 bladder cancer patients.

Temporal trends and clinical determinants of urinary diversion after radical cystectomy.

Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder.

Utilization of intravesical chemotherapy following TURBT: A pre-implementation analysis of American College of Surgeon Commission on Cancer GU quality measures.

Association of interleukin-6 serum levels with local tumor stage and lymph node metastasis of urothelial carcinoma.

Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.

External validation of the Uromonitor®-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management.

Bladder Cancer: Uncovering the Predictive Role of NOTCH as an Emerging Candidate Biomarker for Therapeutic Strategies.

Evolution of Perioperative Outcomes in Robot-Assisted Radical Cystectomy over 20 Years of Experience in a High-Volume Tertiary Robotic Center.

Penile & Urethral Cancers

Human Papillomavirus Genotype Distribution in Penile Cancer: Clinical, Histopathological, Radiological Correlations, and Public Health Perspectives.

An update on the pharmacotherapy of penile cancer.

Renal Cancer

Development and Validation of a Novel Plasma Metabolomic Signature for the Detection of Renal Cell Carcinoma.

Clinical, Pathologic, and Genetic Correlates of Nuclear Grade in von Hippel-Lindau-associated Renal Cell Carcinoma - Beyond the Abstract

A systematic review of global experiences with Medtronic's Hugo™ robotic system for robot-assisted partial nephrectomy.

Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab.

Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium.

Preoperative β2 Microglobulin Is a Prognostic Factor in Patients with Renal Cell Carcinoma and Normal Kidney Function.

An International Delphi Consensus About Tumor Rupture During Robotic Partial Nephrectomy (Researching UnPredictable TUmor RupturE during Robotic Partial Nephrectomy-The RUPTURE Project).

Visfatin Promotes Renal Cell Carcinoma Progression: Evidence from Clinical Samples and Cell Line Models.

Effectiveness of Nivolumab-Based Immunotherapy and Prognostic Stratification by the Meet-URO Score in Real-World Older Patients with Metastatic Renal Cell Carcinoma - Beyond the Abstract

Machine learning-based analysis identifies glucose metabolism-related genes ADPGK as potential diagnostic biomarkers for clear cell renal cell carcinoma.

Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma.

Identification of biomarkers for renal cell carcinoma in plasma samples measured using liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry.

Prostate Cancer

IsoPSA density improves risk stratification and biopsy decision-making for clinically significant prostate cancer.

Diagnostic Value of Micro-Ultrasound in Identifying Local Recurrence After Radical Prostatectomy.

Current Developments in Combining External-Beam Radiotherapy and 177Lu-Labeled PSMA Ligands for Prostate Cancer Treatment.

Genetics-Driven, Intensity-Modulated Adaptive Management of Patients With Metastatic Prostate Cancer.

Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial.

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.

Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer.

A novel application of Decipher testing in HoLEP specimens for risk stratification of incidentally detected prostate cancer.

Beyond PSMA: theranostic cell surface targets in metastatic prostate cancer.

Observational Health Data Analysis of the Cardiovascular Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer: Big Data Analytics Using the PIONEER Platform.

Transcriptomic Profiling of the Tumor Immune Microenvironment Reveals Prognostic Markers in mCRPC Patients Treated with LuPSMA Therapy.

Association of Travel Burden with Definitive Prostate Cancer Treatment: A United States Registry Cohort Study.

Is it time for Canada to revisit its approach to prostate cancer screening?

Real-world clinical outcomes of oligometastatic prostate cancer using SBRT: An Australian experience.

The impact of short-term non-steroidal androgen antagonist therapy on PSMA expression and tumor cellularity studied with dynamic [68Ga]Ga-PSMA-11 PET/MR in hormone-sensitive prostate cancer patients, a preliminary longitudinal prospective study.

Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry.

The future of androgen receptor targeting in prostate cancer: third-generation inhibitors and beyond.

Theranostics 2.0: Target-Driven, Artificial Intelligence-Enabled Cancer Therapy Across Tumor Types - Beyond the Abstract

Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression - Beyond the Abstract

Impact of Metastasis-Directed Therapy Guided by Different PET/CT Radiotracers on Distant and Local Disease Control in Oligorecurrent Hormone-sensitive Prostate Cancer: A Secondary Analysis of the PRECISE-MDT Study - Beyond the Abstract

Prostate Radiotherapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Meta-Analysis of Randomised Controlled Trials - Beyond the Abstract

The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis - Beyond the Abstract

Identifying Cribriform and Intraductal Histology on Magnetic Resonance Imaging-Assisted Biopsy for Patients with Intermediate-Grade Prostate Cancer: Implications for Active Surveillance - Beyond the Abstract

Is [177Lu]Lu-PSMA-617 Redefining Value in mCRPC Care? A Meta-Analysis of Clinical and Economic Endpoints - Beyond the Abstract

Cardiovascular disease and diagnosis of advanced prostate cancer.

Automated machine learning for prostate cancer detection and Gleason score prediction using T2WI: a diagnostic multi-center study.

Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.

Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial.

Next-Generation Nerve-Sparing Techniques in Robotic Radical Prostatectomy: A Contemporary Review.

The role of PSMA PET/CT in staging patients with intermediate-risk prostate cancer.

Robotic-Assisted Radical Prostatectomy in the Elderly Patient-A Study of Functional, Surgical, and Oncological Outcomes in an Australian Cohort.

Evolving Global Trends in Prostate Cancer: Disparities Across Income Levels and Geographic Regions (1990-2019).

Development and validation of the PREVES-HOR Questionnaire: a patient-reported measure of hormone-therapy-related quality of life in prostate-cancer patients undergoing androgen-deprivation therapy.

Upper Tract Tumors

Radical Nephroureterectomy Pentafecta as a Predictor of Upper Tract Urothelial Carcinoma Outcomes Following Radical Surgery.

Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort.

Testicular Cancer

Stimulated Raman histology as a novel method for rapid pathologic examination of unprocessed, fresh testicular biopsies to determine seminoma.

Testicular cancer in Latvia: incidence trends and prognostic outcomes across a 23-year study.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC